{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-007807","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.157032+00:00","generated_at":"2026-06-05T07:43:19.549233+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vericel reports FY2023 revenue $197.5M (+20% YoY); Q4 revenue $65.0M; FY2024 guidance $237-241M","bullets":["Q4 net income $13.0M ($0.26 diluted EPS) vs $5.9M in Q4 2022, up 119%.","FY2023 net loss narrowed to $3.2M from $16.7M; adjusted EBITDA $33.9M (+40%).","MACI net revenue grew 22% to $56.7M in Q4; Burn Care revenue up 31% to $8.3M.","FY2024 total revenue guidance $237-241M; gross margin ~70%; adj. EBITDA margin ~20%.","Cash and investments $152.6M, zero debt; MACI arthroscopic delivery submission accepted by FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-007807","json":"https://secwatch.observer/filing/0001628280-24-007807.json","markdown":"https://secwatch.observer/filing/0001628280-24-007807.md","text":"https://secwatch.observer/filing/0001628280-24-007807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000162828024007807/0001628280-24-007807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000162828024007807/vcel-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T07:43:19.549233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}